Study on the treatment effect of capecitabine and docetaxel on anthracyclines resistant breast cancer
10.3760/cma.j.issn.1008-6706.2017.01.001
- VernacularTitle:卡培他滨联合多西他赛治疗蒽环类耐药性乳腺癌的临床研究
- Author:
Jun YANG
;
Wenfu YANG
- Keywords:
Breast neoplasms;
Capecitabine;
Docetaxel;
Treatment effect
- From:
Chinese Journal of Primary Medicine and Pharmacy
2017;24(1):1-4
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the treatment effects of capecitabine and docetaxel on anthracyclines resistant breast cancer,so as to provide the evidence for the effective treatment of the disease.Methods 1 00 patients with anthracyclines resistant breast cancer were treated in our hospital from January 201 3 to January 201 5,and they were considered as research subjects in this study.The clinical data were analyzed retrospectively.Capecitabine and docetaxel were used for treatment in the treatment group (n =51 ),and there were 49 cases treated with docetaxel in the control group.The indexes were observed including KPS score,the rate of survive to 1 year,TTP and MST.The treatment effects and safety were also compared in these two groups.Results (1 )Before treatment,KPS scores in the treatment group and the control group were (83.6 ±1 .6)points and (83.4 ±1 .7)points respectively,and the difference was not statistically significant (t =0.606,P >0.05).After treatment,the KPS scores were (89.5 ±1 .2)points and (86.4 ±1 .6)points,which of the treatment group was significantly higher than the control group (t =1 0.989,P <0.05).(2)After treatment,1 year survival rate,TTP and MST in the treatment group were significantly higher than those in the control group[1 years survival rate:62.74% vs.40.82%,χ2 =4.815,P <0.05;TTP:(8.5 ±1 .1 )months vs.(6.3 ±1 .2)months,t =9.563,P <0.05;MST:(1 5.6 ±1 .2)months vs.(1 5.6 ±1 .2)months,t =1 0.871 ,P <0.05].(3)The treatment efficiency and the clinical benefit rate in the treatment group were significantly higher than those in the control group (the treatment efficiency:90.1 9% vs.63.27%,χ2 =1 0.234,P <0.05;clinical benefit rate:94.1 2% vs.73.47%,χ2 =6.466,P <0.05).(4)However,there was no difference about the ratio of adverse reaction between the two groups (bone marrow suppression:1 3.73% vs.1 2.24%,χ2 =0.048,P >0.05;nausea and vomiting:1 1 .76% vs.1 4.29%,χ2 =0.1 04,P >0.05;constipation:1 9.61 % vs.1 8.37%,χ2 =0.025,P >0.05;alopecia:21 .57% vs.20.41 %,χ2 =0.020,P >0.05;indigestion:25.49% vs.22.45%,χ2 =0.1 27,P >0.05;joint pain:1 5.67% vs.20.41 %,χ2 =0.378,P >0.05 ).Conclusion Capecitabine and docetaxel are used in the treatment of anthracyclines resistant breast cancer,and it can delay the patients'condition and improve the survival time.Besides,it is also safe and effective.Therefore,this method is worth to promote and use in clinic.
